The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1215
Duloxetine (Cymbalta) for Diabetic Neuropathic Pain
The full article is available to subscribers Subscriber Login   

Duloxetine hydrochloride (Cymbalta – Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) available for treatment of depression,1 has also been approved by the FDA for treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Duloxetine is one of two drugs approved specifically for management of neuropathic pain due to diabetes; the other, pregabalin (Lyrica – Pfizer), will be marketed soon and will be reviewed in the next issue of The Medical Letter.

OTHER TREATMENTS FOR NEUROPATHIC PAIN — Drugs used to treat neuropathic pain include tricyclic antidepressants, anticonvulsants, opioid analgesics and topical preparations such as capsaicin (Zostrix-HP, and others)2 and lidocaine. Lidocaine 5% transdermal patches (Lidoderm) and gabapentin (Neurontin, and others) are FDA-approved for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Duloxetine (Cymbalta) for Diabetic Neuropathic Pain
Article code: 1215b
 Electronic, downloadable article - $25